Production (Stage)
Theravance Biopharma, Inc.
TBPH
$9.30
-$0.19-2.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.30% | -2.22% | 13.40% | -105.26% | -105.11% |
| Total Depreciation and Amortization | -5.72% | 5.28% | 7.31% | -2.68% | 0.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.09% | -40.59% | 118.19% | 102.60% | 102.52% |
| Change in Net Operating Assets | 1,147.06% | 344.06% | -94.41% | -94.97% | -113.40% |
| Cash from Operations | 293.63% | 57.27% | 92.35% | 94.83% | 90.24% |
| Capital Expenditure | 85.31% | 86.66% | 60.57% | 58.73% | -30.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -100.00% | -55.62% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.72% | 139.77% | -142.31% | -98.69% | -97.43% |
| Cash from Investing | -5.44% | 137.57% | -157.12% | -98.77% | -97.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.29% | -1.94% | -18.82% | -22.21% | -22.82% |
| Repurchase of Common Stock | 98.44% | 98.44% | 83.69% | 75.97% | 22.47% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.87% | 98.74% | 83.93% | 92.87% | 82.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.43% | 99.32% | 86.07% | -423.71% | -243.44% |